PCOS and Implantation Failure: What the Term Means, and What Trials Show

What Does “Recurrent Implantation Failure” Actually Mean?

Recurrent implantation failure (RIF) was first defined in 2014 as failure to achieve a clinical pregnancy after transferring at least four good-quality embryos across a minimum of three fresh or frozen cycles, in a woman under 40 — a specific, numeric IVF criterion, not a general description of difficulty conceiving (Coughlan et al., 2014). Reproductive medicine has since revised even that definition: a 2023 ESHRE working group replaced the fixed embryo-and-cycle count with a probability-based threshold, recommending RIF be considered for further investigation once a couple’s own cumulative predicted chance of a successful implantation — calculated from the specific embryos already transferred — passes 60% and still has not happened (Cimadomo et al., 2023).

Two professional definitions, less than a decade apart, is the clearest evidence that RIF does not reduce to a number a person can apply to their own situation from outside a fertility clinic. Both describe something that happens inside IVF, after embryos already judged good-quality have already been transferred more than once — not six months, or even a year, of trying to conceive without IVF, a separate, well-defined question with its own fertility-specialist referral timeline. Implantation failure is one narrow piece of the wider PCOS fertility picture, covering ovulation, egg quality and pregnancy risk beyond this specific question.

You may see PCOS written as polyendocrine metabolic ovarian syndrome (PMOS), after a 2026 global consensus of more than 50 organisations renamed it. Every figure on this page applies under either name — only the label changed.

Is “Implantation Failure” the Same as Not Being Pregnant Yet, or a Miscarriage?

Three different situations get called “implantation failure” in everyday conversation, and only one of them matches either clinical definition above. The first is simply not having conceived yet after a limited number of natural cycles — normal variation in time-to-pregnancy, not a failure of implantation. When that pattern actually warrants stepping up to a specialist work-up — including why PCOS often shortens the usual wait — is answered separately from this page. The second is a biochemical pregnancy: a brief positive test, sometimes confirmed on blood work, that does not progress to a visible pregnancy on ultrasound — technically evidence that implantation began and then stopped, which is a different event from RIF’s “never implanted at all” pattern. The third is a clinically confirmed pregnancy loss after implantation and a visible gestational sac — a miscarriage, not an implantation problem. The PCOS miscarriage rate and what’s modifiable is answered in full on its own page rather than repeated here.

Does PCOS Affect Endometrial Receptivity, Separately From Egg Quality?

Two mechanistic studies suggest PCOS changes gene activity inside the endometrium in ways that plausibly affect receptivity, independent of whatever is happening to the egg. That distinction matters because the best-designed comparisons available find egg and embryo quality in PCOS largely equivalent to controls — so if something about PCOS does affect implantation specifically, the endometrium is the more biologically plausible place to look, not the oocyte.

The clearest single mechanism comes from HOXA10, a gene required for normal endometrial receptivity to an embryo. In laboratory experiments, testosterone directly suppressed HOXA10 expression, while endometrial biopsies taken from women with PCOS showed measurably lower HOXA10 mRNA than would be expected without that androgen exposure (Cermik et al., 2003). A separate microarray study comparing endometrial samples from women with PCOS against fertile controls found a broader pattern behind that single gene: several progesterone-regulated genes important to receptivity — including MIG6, LIF, GAB1, S100P and claudin-4 — were significantly lower in PCOS endometrium, a pattern the study’s authors described as progesterone resistance (Savaris et al., 2011).

Plausible biology is not the same as a demonstrated clinical effect, and the honest gap here is real: neither study measured implantation or live-birth rates directly, both worked from small samples, and no trial has isolated a PCOS-specific receptivity effect on pregnancy outcomes from the other factors — insulin resistance, BMI, age — that travel alongside a PCOS diagnosis. The current, accurate answer is that a plausible molecular mechanism exists and a measured clinical effect on implantation rates has not been established.

Endometrial thickness is a related but genuinely different measurement from receptivity, and it is worth not conflating the two. A thick endometrial lining in PCOS is a structural marker driven by chronic anovulation — unopposed oestrogen building the lining for months without a progesterone-triggered reset — while receptivity, as studied above, is a question of gene activity inside that tissue. A lining can measure within a normal range on ultrasound and still carry the gene-expression pattern described above; the two properties have not been shown to move together.

What Does the Trial Evidence Say About Treatments Marketed for Implantation Failure?

Four products and procedures dominate the implantation-failure market, and for every one of them, the strongest single trial available found no meaningful benefit, or the earlier positive result turned out to rest on since-retracted data.

Endometrial scratch — deliberately injuring the endometrial lining with a biopsy instrument before a transfer cycle, on the theory that the resulting inflammatory response improves receptivity. A pragmatic, multicentre randomised trial of 1,364 women found live birth in 26.1% of the scratch group and 26.1% of the control group — a difference of zero (adjusted odds ratio 1.00, 95% CI 0.78–1.27) — while a median pain score of 3.5 out of 10 was reported for the procedure itself (Lensen et al., 2019). A 2023 meta-analysis pooling 41 mostly smaller trials and 9,084 women reached the opposite conclusion, reporting higher clinical pregnancy (OR 1.34) and live birth (OR 1.30) with scratch (Maged et al., 2023). When one very large, low-bias trial and a meta-analysis of many smaller ones disagree this sharply, the large trial is generally the more trustworthy answer — smaller trials carry more risk of inconsistent technique and publication bias, exactly the pattern scratch shows here.

Intralipid infusion — an intravenous fat-emulsion drip given around transfer, intended to dampen uterine natural killer cell activity. A 2021 meta-analysis of five small randomised trials and roughly 840 women reported a higher clinical pregnancy rate (RR 1.48) and live birth rate (RR 1.85) with intralipid (Han et al., 2021). One of the trials feeding that pooled result was formally retracted in September 2025 — a Saudi Arabian RCT on intralipid in recurrent implantation failure that had been part of this evidence base since 2020 (retraction notice, Gynecol Endocrinol, 2025). No intralipid trial approaches the size or quality of the scratch trial above, so the honest summary is a positive result resting on a handful of small trials, one of which no longer counts.

Peri-implantation steroids — a short course of oral glucocorticoids around transfer, intended to suppress endometrial inflammation. The current Cochrane review, pooling 16 randomised trials and 2,232 couples, found the evidence “very low-certainty” on every outcome measured: uncertain whether live birth improved (OR 1.37, 95% CI 0.69–2.71), no clear difference in clinical pregnancy, and no clear difference in miscarriage or multiple pregnancy (Boomsma et al., 2022). The review’s own conclusion is that there is insufficient evidence that glucocorticoids change outcomes in IVF or ICSI cycles.

Endometrial receptivity array (ERA) testing — a biopsy-based genetic test marketed to identify each patient’s personal “window of implantation” so a frozen transfer can be retimed to match it. A double-blind randomised trial of 767 patients with a euploid embryo found live birth in 58.5% of the ERA-timed group against 61.9% of the standard-timing group — not a significant difference, and numerically in the opposite direction from what the test claims to deliver (Doyle et al., 2022). The trial’s own conclusion states plainly that the findings do not support routine use of receptivity testing to guide transfer timing.

Does PCOS Phenotype Change Any of This?

No study cited above sorted its participants by PCOS phenotype, so a phenotype-specific answer would be invented rather than evidence-based. The insulin-resistant phenotype carries the heaviest androgen and inflammatory burden of the recognised phenotypes, making it biologically plausible that the receptivity mechanisms above apply more strongly there than in a leaner presentation — but plausible is the ceiling of what can honestly be said. Nobody has tested implantation or live-birth outcomes in IVF stratified by phenotype, so this remains genuinely open.

Who Actually Needs This Investigated, and What This Page Does Not Mean

The 2023 international PCOS guideline sets the broader standard for PCOS-related fertility care — ovulation induction, first-line medication choice — but it does not specifically address recurrent implantation failure, since RIF only exists as a phenomenon within IVF, a treatment stage the guideline covers in less depth than a dedicated ART body does (Teede et al., 2023). That dedicated body’s own recommendation is to restrict investigations and interventions for RIF to situations with a clear rationale and supporting data, rather than offering the full menu to anyone who asks — and that framing, more than any single test result above, is the practical takeaway. A handful of points worth being direct about:

• One failed transfer is not RIF, under either definition in Table 1. Neither professional body applies the term to a single cycle, however discouraging that cycle felt.
• A PCOS diagnosis does not mean a receptivity problem is present. The mechanistic evidence above describes a plausible pathway, not something confirmed to affect every person with PCOS undergoing IVF.
• An unproven intervention is not the same as a harmful one. The evidence above shows these four approaches unproven at the scale claimed, not dangerous — though each carries its own safety considerations worth raising with the clinic providing it, not decided from this page.
• This page does not diagnose anyone with implantation failure. Whether the specific definition in Table 1 applies to an individual situation, and what — if anything — is worth investigating from there, is a conversation for the fertility clinic managing that person’s actual embryo transfers, not something a general article can resolve.